US Patent

US12180219 — Process for preparing beta 3 agonists and intermediates

Composition of Matter · Assigned to Merck Sharp and Dohme LLC · Expires 2034-03-12 · 8y remaining

Vulnerability score 17/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects a process for making beta-3 agonists and intermediates using ketoreductase biocatalyst enzymes.

USPTO Abstract

The application is directed to efficient and economical processes as described in more detail below for the preparation of the beta 3 agonists of the formula of I-7 and intermediate compounds that can be used for making these agonists. The present disclosure relates to a process for making beta-3 agonists and intermediates using ketoreductase (KRED) biocatalyst enzymes and methods of using the biocatalysts.

Drugs covered by this patent

Patent Metadata

Patent number
US12180219
Jurisdiction
US
Classification
Composition of Matter
Expires
2034-03-12
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Merck Sharp and Dohme LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.